C. Genestie

C. Genestie, A. Leary, M. Devouassoux‐Shisheboran, 2018, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

P. Pollock, C. Genestie, H. Kitchener, 2022, Modern Pathology.

Outcome of HER2-positive breast cancer patients following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval.

C. Genestie, D. Khayat, J. Spano, 2012 .

Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors

C. Genestie, F. Guyon, F. Chibon, 2018, Modern Pathology.

Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy

C. Haie-meder, C. Genestie, E. Deutsch, 2020, Journal of clinical medicine.

Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors

C. Genestie, P. Kelly, J. Kopchick, 2010, Proceedings of the National Academy of Sciences.

[Breast chondrosarcoma: a case report and review].

C. Genestie, J. Gelberg, B. Zafrani, 2001, Annales de pathologie.

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, medRxiv.

Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.

E. Touboul, C. Genestie, J. Lefranc, 2004, International journal of radiation oncology, biology, physics.

Proteomic analysis of BRCA1‐depleted cell line reveals a putative role for replication protein A2 up‐regulation in BRCA1 breast tumor development

C. Genestie, M. Stern, D. Stoppa-Lyonnet, 2010, Proteomics. Clinical applications.

[Mixed mullerian tumours of the endometrium. Four cases developed while on tamoxifen treatment].

C. Genestie, F. Walker, 2004, Gynecologie, obstetrique & fertilite.

Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.

C. Genestie, A. Leary, P. Morice, 2018, Anticancer research.

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

C. Genestie, H. Mackay, A. Fyles, 2022, British Journal of Cancer.

Results After Conservative Surgery of Stage II/III Serous Borderline Ovarian Tumors

C. Genestie, A. Leary, P. Morice, 2020, Annals of Surgical Oncology.

Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.

C. Genestie, A. Leary, P. Morice, 2020, Gynecologic oncology.

Feasibility of ovarian cryopreservation in borderline ovarian tumours.

C. Genestie, P. Morice, C. Uzan, 2008, Human reproduction.

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer

C. Genestie, Naveena Singh, K. K. van de Vijver, 2019, Histopathology.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

C. Haie-meder, C. Genestie, S. Culine, 2016, Gynecologic oncology.

[Epidermoid carcinoma of the uterine cervix at operable bulky stages IB and II treated with combined primary radiation therapy and surgery].

E. Touboul, C. Genestie, E. Deniaud-Alexandre, 2002, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies

C. Genestie, T. Leblanc, P. Touraine, 2019, Haematologica.

Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration

C. Genestie, S. Richard, J. Salleron, 2018, Modern Pathology.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

C. Genestie, T. Leblanc, P. Touraine, 2019, Human reproduction.

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.

Cyrus Chargari, C. Genestie, A. Leary, 2018, The oncologist.

Gliomatosis Peritonei: A Particular Entity With Specific Outcomes Within the Growing Teratoma Syndrome

C. Genestie, P. Morice, C. Uzan, 2015, International Journal of Gynecologic Cancer.

Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases

C. Genestie, C. Balleyguier, A. Leary, 2015, Annals of Surgical Oncology.

Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer

E. Touboul, E. Touboul, C. Genestie, 2005, Breast Cancer Research and Treatment.

C. Genestie, A. Leary, Y. Kametani, 2021, European Journal of Gynaecological Oncology.

Networking for ovarian rare tumors: a significant breakthrough improving disease management

N. Chiannilkulchai, C. Genestie, F. Penault-Llorca, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[Glandular lesions of the uterine cervix: Case 4].

C. Genestie, P. Duvillard, C. Kacem, 2016, Annales de pathologie.

[Endometrial stromal tumor associated with rhabdoid phenotype and and zones of "sex cord-like" differentiation].

C. Genestie, C. Rosty, J. Blondon, 1998, Annales de pathologie.

Cisplatin‐based chemotherapy regimen (DECAV) for uterine sarcomas

C. Haie-meder, C. Genestie, A. Le Cesne, 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas

C. Haie-meder, C. Genestie, A. Le Cesne, 2002, International Journal of Gynecologic Cancer.

Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients.

C. Haie-meder, C. Genestie, A. Leary, 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.

C. Genestie, P. Pautier, S. Gouy, 2022, Gynecologic oncology.

[Initial management of gynecologic cancers: reference guides of the Société Française d'Oncologie Gynécologique (SFOG) ].

C. Haie-meder, I. Barillot, C. Genestie, 2008, Gynecologie, obstetrique & fertilite.

Pathobiology of ovarian carcinomas

C. Genestie, M. Devouassoux-Shisheboran, 2015, Chinese journal of cancer.

Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems.

B Asselain, A Fourquet, C. Genestie, 1998, Anticancer research.

Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients

E. Touboul, C. Genestie, F. Coulet, 2006, British Journal of Cancer.

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

C. Genestie, J. Adam, A. Dunant, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary

C. Genestie, F. Petit, J. Cohen‐Tannoudji, 2019, Oncogene.

Ovarian Cancer: A Heterogeneous Disease

C. Genestie, J. Scoazec, A. Leary, 2017, Pathobiology.

Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.

C. Genestie, G. Le Teuff, A. Leary, 2022, Gynecologic oncology.

Management of Endometrial Cancer: French Society of Onco-Gynecology‘s Evaluation through a Delphi Survey

C. Genestie, F. Guyon, C. Uzan, 2022, Journal of clinical medicine.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

P. Pollock, C. Genestie, H. Mackay, 2018, Modern Pathology.

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy

C. Haie-meder, Cyrus Chargari, C. Genestie, 2016, Clinical & Experimental Metastasis.

Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers

C. Genestie, J. Scoazec, A. Leary, 2020, Virchows Archiv.

Rare DICER1 and Absent FOXL2 Mutations Characterize Ovarian Juvenile Granulosa Cell Tumors

C. Genestie, I. Treilleux, I. Ray-Coquard, 2020, The American journal of surgical pathology.

Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours

C. Genestie, A. Dunant, J. Scoazec, 2019, British Journal of Cancer.

Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.

C. Genestie, F. Guyon, A. Leroux, 2022, Gynecologic oncology.

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

C. Genestie, A. Dunant, A. Leary, 2020, Cancer Immunology, Immunotherapy.

Metabolic features of cancer cells impact immunosurveillance

C. Genestie, G. Kroemer, J. Adam, 2021, Journal for ImmunoTherapy of Cancer.

A mesocolic leiomyosarcoma metastatic to the breast: case report and review of the literature.

C. Genestie, S. Taillibert, D. Khayat, 2000, Anticancer research.

Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions

C. Genestie, P. Vielh, V. Suciu, 2016, Cytopathology : official journal of the British Society for Clinical Cytology.

FOXL2 mutations lead to different ovarian phenotypes in BPES patients: Case Report.

C. Genestie, R. Veitia, P. Touraine, 2010, Human reproduction.

Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements

C. Genestie, A. Leary, P. Morice, 2022, Annals of Surgical Oncology.

Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management

C. Genestie, A. Leary, P. Morice, 2021, Annals of Surgical Oncology.

Brenner Borderline Ovarian Tumor: A Case Series and Literature Review

C. Genestie, A. Leary, P. Morice, 2021, Annals of Surgical Oncology.

Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.

C. Genestie, A. Dunant, E. Lanoy, 2020, Gynecologic oncology.

Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients.

C. Genestie, D. Pezet, P. Morice, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).

C. Genestie, D. Berton, I. Ray-Coquard, 2020, Gynecologic oncology.

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types

C. Genestie, A. Leary, P. Morice, 2017, Gynecologic oncology reports.

Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center.

C. Haie-meder, C. Genestie, A. Bertaut, 2021, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, R. Rouzier, F. Guyon, 2018, Bulletin du cancer.

False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology

C. Genestie, A. Leary, P. Morice, 2021, BMC cancer.

Clinical transfer of AGuIX®-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework.

O. Tillement, C. Genestie, F. Lux, 2023, Nanomedicine : nanotechnology, biology, and medicine.

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment.

C. Haie-meder, I. Dumas, Cyrus Chargari, 2017, The oncologist.

Estradiol promotes cell survival and induces Greb1 expression in granulosa cell tumors of the ovary through an ERα‐dependent mechanism

C. Genestie, J. Katzenellenbogen, I. Treilleux, 2021, The Journal of pathology.

Cervical Cancer and Fertility-Sparing Treatment

C. Genestie, A. Leary, P. Morice, 2021, Journal of clinical medicine.

Neoadjuvant chemotherapy in fertility-sparing management of FIGO 2018 stage IB2 cervical cancer

C. Genestie, P. Morice, S. Gouy, 2022, International Journal of Gynecological Cancer.

Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy.

C. Haie-meder, C. Genestie, A. Leary, 2020, Gynecologic oncology.

A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.

C. Genestie, D. Berton, V. Serra, 2023, Gynecologic oncology.

Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).

C. Genestie, I. Treilleux, I. Ray-Coquard, 2022, Gynecologic oncology.

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

C. Genestie, S. Broutin, C. Balleyguier, 2021 .

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience

C. Haie-meder, Cyrus Chargari, C. Genestie, 2018, International Journal of Gynecologic Cancer.

In vivo imaging of uterine cervix with a Mueller polarimetric colposcope

Angelo Pierangelo, Jérémy Vizet, Jean Rehbinder, 2017, Scientific Reports.

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

C. Genestie, D. Berton, F. Guyon, 2023, Gynecologic oncology.

[Histological and molecular classification of endometrial carcinoma and therapeutical implications].

C. Genestie, A. Leary, A. Auguste, 2017, Bulletin du cancer.

[Adult multi-nuclear cell hepatitis. A study in 17 patients].

C. Genestie, T. Tordjmann, J. Trinchet, 1998, Gastroenterologie clinique et biologique.

Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.

E. Touboul, C. Genestie, M. Antoine, 2001, International journal of radiation oncology, biology, physics.

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer

C. Genestie, A. Leary, L. Lacroix, 2023, International journal of molecular sciences.

Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors.

C. Haie-meder, I. Dumas, Cyrus Chargari, 2017, Gynecologic oncology.

2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, Ovarian cancer.

Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy.

C. Genestie, R. Rouzier, I. Ray-Coquard, 2017, European journal of gynaecological oncology.

CREB fusion–associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype

C. Genestie, I. Ray-Coquard, A. Agaimy, 2023, Virchows Archiv.

Early-onset gynecological tumors in DNA repair-deficient xeroderma pigmentosum group C patients: a case series

C. Genestie, B. Borghese, A. Yurchenko, 2023, Communications Medicine.

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis

M. Rubin, O. Elemento, C. Genestie, 2020, Cells.

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers.

C. Genestie, A. Leary, P. Morice, 2018, The oncologist.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type

C. Genestie, A. Leary, P. Morice, 2018, International Journal of Gynecologic Cancer.

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?

C. Genestie, A. Leary, P. Morice, 2017, Gynecologic Oncology Reports.

Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact.

C. Haie-meder, I. Dumas, C. Genestie, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?

C. Genestie, A. Leary, P. Morice, 2019, AntiCancer Research.

[Fertility preservation in cervical cancer, analysis of 30 years of practice and immersion in future developments.]

C. Genestie, C. Balleyguier, A. Leary, 2021, Gynecologie, obstetrique, fertilite & senologie.

A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers

C. Genestie, A. Scarsbrook, R. Sun, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

K. Moore, C. Genestie, I. Treilleux, 2023, Cell Death & Differentiation.

[Gynecopathology. Case 5. Epithelioid smooth muscle tumors].

C. Genestie, M. Devouassoux-Shisheboran, 2012, Annales de Pathologie.

First Demonstration of in vivo Mueller Polarimetrie Imaging on Human Uterine Cervix

C. Haie-meder, C. Genestie, A. Pierangelo, 2018, 2018 Conference on Lasers and Electro-Optics (CLEO).

Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors

C. Genestie, P. Kelly, J. Kopchick, 2010, Proceedings of the National Academy of Sciences.

[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].

C. Genestie, F. Guyon, S. Le Guellec, 2023, Bulletin du cancer.

[Current post-surgical treatment strategies in first-line ovarian cancer].

C. Genestie, A. Leary, P. Morice, 2023, Bulletin du cancer.

Un explorateur visuel cognitif (MIcroscope COgnitif - MICO) pour l'histopathologie. Application au diagnostic et à la graduation du cancer du sein.

Catherine Genestie, Daniel Racoceanu, Ludovic Roux, 2011 .

[Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group].

J. Blay, C. Genestie, F. Guyon, 2023, Bulletin du cancer.

[Uterin sarcoma, high-grade stroma, indifferenciated, referential].

C. Genestie, F. Guyon, I. Ray-Coquard, 2023, Bulletin du cancer.

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment.

C. Haie-meder, I. Dumas, Cyrus Chargari, 2017, The oncologist.

[Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].

C. Genestie, C. Durdux, C. Chargari, 2022, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer

C. Genestie, J. Adam, A. Leary, 2020, Cancers.

[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].

C. Genestie, I. Ray-Coquard, C. Genestie, 2016, Bulletin du cancer.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, F. Guyon, C. Rousset-Jablonski, 2018, Bulletin du cancer.

2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers

C. Genestie, I. Ray-Coquard, F. Coulet, 2022, Ovarian cancer.

Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): Prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG).

C. Genestie, D. Berton, I. Ray-Coquard, 2020 .

Male adnexal tumor of probable Wolffian origin: a new entity in males similar to female adnexal tumor of probable Wolffian origin

C. Genestie, M. Sibony, Christina Kanaan, 2020, Virchows Archiv.

Factors associated with the collection of isolated immature oocytes during ovarian tissue cryopreservation

C. Genestie, C. Poirot, M. Prades, 2023, Journal of Assisted Reproduction and Genetics.

[Application in France of the 2021 European recommendations on endometrial cancer].

Cyrus Chargari, C. Genestie, F. Guyon, 2022, Bulletin du cancer.